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The patent foramen ovale (PFO) is a normal interatrial communication during fetal life that persists after birth in
approximately 1 of every 4 adults. PFO is a potential route for embolic transit from the systemic venous circula-
tion to the brain. Though there is compelling circumstantial evidence implicating PFO, the precise role of PFO in
the pathogenesis of cryptogenic stroke is not yet established. Several randomized trials of transcatheter PFO
closure versus medical management are ongoing. Results of these trials may improve our ability to select the best
treatment for individual patients. Further well-designed studies are necessary to address several unresolved issues
related to PFO stroke and PFO migraine pathophysiology, and to identify the patients who would most likely benefit
from PFO closure. The purpose of this review is to summarize contemporary understanding, discuss current treat-
ments, and explore some of the knowledge gaps pertaining to the clinical significance of PFO. (J Am Coll Cardiol
2012;59:1665–71) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.085Prevalence and Anatomic Aspects
The patent foramen ovale (PFO) is an integral part of
normal fetal circulation. Normally, a portion of the blood
from the inferior vena cava passes from the right atrium to
the left atrium through the PFO during fetal life, bypassing
the lungs. Pulmonary blood flow increases greatly during
neonatal circulatory transition, causing increased left atrial
pressure. The resulting atrial pressure differences compress
the septum primum against the septum secundum, func-
tionally closing the PFO. Anatomic closure of the PFO
occurs later in infancy in the majority of the population, but
autopsy (1) and detailed contrast echocardiography studies
demonstrate that anatomic closure is incomplete in approx-
imately 1 of every 4 adults. Therefore, PFO should be
considered a normal anatomic variant and not a pathological
finding in the absence of possible paradoxical embolism or
other specific clinical conditions.
PFO diameters in formalin-fixed hearts at autopsy range
from 1 to 19 mm, and the average PFO size is larger in older
adults (1). PFO anatomy is variable. The opening on the left
atrial side tends to be crescentic in shape. In most cases, the
flap-like septum primum barely covers the opening of the
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accepted September 13, 2011.fossa ovalis when the septum primum is pushed toward
the left atrial side of the septum. However, the length of the
“tunnel” from the ridge of the fossa ovalis on the right atrial
side to the left atrial opening can vary depending on the
fixation location of the upper edges of the incompletely
fused septum primum. The “flap” of the septum primum
acts like a 1-way door, which can open a variable amount
toward the left atrium depending on the force directing it in
that direction, or seal the interatrial opening when it closes
against the septum secundum. Under normal physiological
conditions, the left atrial-to-right-atrial pressure differential
gently pushes the thin septum primum against the septum
secundum and, except for very brief periods in each cardiac
cycle, seals the potential opening of the PFO. There is only
trivial shunting of blood between the atria. Actions, such as
the release of a Valsalva maneuver, can transiently reverse
the normal left-to-right pressure gradient and cause an
exaggerated transient leftward shift of the free edge of the
septum primum with apparent enlargement of the orifice of
the PFO. However, the actual maximal size of the opening
of the PFO cannot be accurately measured without mechan-
ically pushing the septum primum away from the septum
secundum, either with a low-pressure balloon in the cardiac
catheterization laboratory or with a probe during postmor-
tem examination. The septum primum may be aneurysmal
(Online Video 1) and may have single or multiple openings
in addition to the gap of incomplete fusion with the septum
secundum, which is the actual PFO.
The physiological implications of a PFO vary depending
on loading conditions and streaming. Transthoracic or trans-
esophageal echocardiography (TEE) or transcranial Doppler
ultrasound has been used for diagnosis and assessment of
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saline contrast increases the diag-
nostic sensitivity by enhancing
echocardiographic detection of
the trivial intermittent right-to-left
shunting across a typical PFO. Ag-
itated saline contrast injected intra-
venously during Valsalva maneuver
with release of straining when con-
trast is visualized in the right atrium
increases sensitivity. Visualization of
contrast microbubbles passing from
the right to left atrium through the
visualized foramen ovale during the
release phase is diagnostic of an in-
teratrial communication. In clinical practice, the actual site of
right-to-left shunting may not be convincingly visualized or
recorded for technical reasons. If a recording convincingly
demonstrates microbubbles appearing in the left atrium
immediately after arriving in the right atrium, then the
presence of a PFO can be presumed (Online Video 2). If
bubbles appear in the left atrium before or 5 beats after
they appear in the right atrium, then the possibility of
anomalous venous connection to the left atrium or pulmo-
nary arteriovenous malformations must be considered.
Contrast injected through an upper extremity vein may be
washed away by contrast-free blood flow from the inferior
vena cava directed by the eustachian valve, creating a
false-negative result (2). Injection of contrast via the femoral
vein has been proposed to enhance detection by TEE, with
the streaming effect of directed inferior vena cava flow to the
region of the fossa ovalis and through a patent foramen (3).
Abbreviations
and Acronyms
ASA  atrial septal
aneurysm
CS  cryptogenic stroke
MRI  magnetic resonance
imaging




TIA  transient ischemic
attack
Figure 1 Schematic Image of PFO
The arrow indicates the location of the patent foramen ovale (PFO). See
accompanying Online Video 1. LA  left atrium; LV  left ventricle; MV 
mitral valve; RA  right atrium; RV  right ventricle; TV  tricuspid valve.Relationship With Stroke
Approximately 800,000 people experience stroke each year
in the United States; approximately 610,000 of these are
first attacks, and 185,000 are recurrent attacks (4). Transient
ischemic attack (TIA), a temporary episode of neurological
dysfunction likely caused by reduced blood flow to the brain
or spinal cord without permanent damage to brain tissue,
occurs in an additional 200,000 to 500,000 per year in the
United States (4). However, definitions of TIA and stroke
can vary somewhat depending on whether a clinical or
anatomic viewpoint is used. Patients in many studies had
not routinely had anatomic/brain magnetic resonance im-
aging (MRI) evaluations and were categorized as having had
a TIA if they had transient clinical symptoms, even if an
MRI was not performed or showed only small lesions.
There are multiple possible causes of ischemic strokes,
and a clear etiology often cannot be found in the individual
patient. It is estimated that approximately 25% to 40% of
strokes are of undetermined pathogenesis, and are com-
monly termed cryptogenic strokes (CS). PFO is a potential
route for embolic transit of platelet aggregations, thrombi,
gas bubbles, or other particulate matter from the systemic
venous circulation to the brain. PFO also could be a nidus
for potentially embolic thrombus formation in situ.
The association of PFO with CS was first reported in
1988 by Lechat et al. (5). They studied the prevalence of
PFO as detected by contrast echocardiography in 60 adults
55 years of age with ischemic stroke and compared the
results with a control group of 100 subjects. The prevalence
of PFO detected by their methodology was significantly
Figure 2 Diagnosis of PFO
Intravenously injected agitated saline contrast increases the diagnostic sensi-
tivity by enhancing transthoracic or transesophageal echocardiographic detec-
tion of the intermittent right-to-left shunting across the patent foramen. See
accompanying Online Video 2. See text. bpm  beats/min; other abbreviations
as in Figure 1.higher in patients with stroke (40%) than in controls (10%).
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PFO prevalence was 56%; in those with no identifiable
cause who had a risk factor (migraine, mitral valve prolapse,
contraceptive usage), the prevalence was 40%; and in pa-
tients in whom a cause for stroke was identified, PFO
prevalence was 21% (5). Petty et al. (6), in a TEE study of
116 patients with cerebral infarction, showed similar results.
PFO was found in 40% of patients with infarcts of uncertain
cause and in 25% of patients with infarcts of known cause.
When the analysis was restricted to patients who underwent
Valsalva maneuver, PFO with right-to-left or bidirectional
shunt was found in 50% of patients with CS (6).
Several other studies have shown an association between
PFO and CS (7–9), and have suggested a role for PFO in
stroke pathophysiology. A meta-analysis of retrospective
studies showed that patients 55 years who sustained a CS
had a PFO prevalence 6 times greater than that of
patients with other forms of stroke (10). Handke et al.
(11) showed that the prevalence was higher among
patients with CS than among those with stroke of known
cause in both younger and older patients, suggesting
paradoxical embolism as a cause of stroke. Taken to-
gether, these studies do suggest that PFO is more
common in patients with a CS than in the general
population (approximately 50% to 60% vs. 20% to 25%)
or in patients with stroke of determined origin.
Despite the compelling circumstantial evidence implicat-
ing PFO in the pathogenesis of CS, prospective studies have
not necessarily demonstrated an association. In a prospec-
tive population-based study by Meissner et al. (12), PFO
was not found to be an independent risk factor for future
cerebrovascular events in the general population after cor-
rection for age and comorbidity. This is not surprising,
however, since PFO is found in about 25% of the general
population, and only a tiny fraction of people with PFO
may have the additional factors that increase the risk of an
embolus traversing or forming in the PFO. Prophylactic
closure of an incidentally discovered PFO is not recom-
mended. A pooled analysis of prospective studies (8,13) did
not find an increased risk of recurrent stroke among cryp-
togenic stroke patients with a PFO compared with those
without PFO (14). However, this analysis does not address
whether closure of a PFO in patients shown to be at risk for
a paradoxical embolus (previous history) lowers the risk of
recurrent stroke specifically in those patients. Small series of
uncontrolled and relatively short-term evaluations have
demonstrated a reduction in recurrence rate of focal neuro-
logical events in patients with an atrial septal defect or PFO
who had experienced multiple recurrent events and under-
went transcatheter defect closure (15).
Finally, optimal management of a thromboembolus caught
in transit across a PFO (impending paradoxical embolism) is
also not well defined. A systematic review of case reports
and observational studies on this subject has compared
mortality and systemic embolism between treatments (16).
On multivariate regression models, surgical treatment dem-onstrated a nonsignificant trend toward improved survival
compared with anticoagulation alone (16).
Atrial Septal Aneurysm and PFO Size
The atrial septal aneurysm (ASA) is defined as a mobile
protrusion of the septum primum tissue into the atrium
measuring at least 10 to 15 mm or a phasic septal excursion
of at least 15 mm occurring at some point during the
cardiorespiratory cycle (17). Definitions for ASA vary
widely in the literature (10- to 15-mm total excursion, 10 to
15 mm in 1 direction or the other, etc.). In our opinion, a
30-mm total excursion is too stringent a definition. A more
accurate term may be atrial septal hypermobility since the
septum really does not have a true aneurysm, but ASA is
currently entrenched in the literature. ASA is frequently
associated with PFO. In patients with cerebral ischemia and
ASA, ASA (with or without PFO) is often the only
potential cardioembolic source identified on TEE (18).
Concomitant presence of an ASA, small additional atrial
septal defects, a large eustachian valve, or Chiari strands
have all been postulated (but not conclusively proven) to be
significant in the presence of a PFO (19). Chiari strands,
congenital remnants of the right valve of the sinus venosus,
can be associated with both PFO and ASA, and are believed
by some to facilitate paradoxical embolism (20).
The combination of PFO and ASA emerged as a pre-
dictor of increased risk for recurrent stroke in some reports
(8,11), but in other studies, neither PFO alone nor in
combination with ASA was associated with an increased
risk for stroke (21). The association of ASA with stroke
recurrence remains debatable. Homma et al. (13) demon-
strated that neither the degree of shunt nor concomitant
ASA is associated with an increased risk of stroke recurrence
or death. Published literature is also inconsistent regarding
foramen size as a CS risk factor. PFO maximal diameter
during the Valsalva provocation has been shown on TEE in
some studies to be greater in patients with CS (22), whereas
others have not shown this association (13,23). Further
studies are required to determine whether PFO size mea-
sured by any particular technique or other anatomic/
physiological features are useful to stratify risk for CS.
Recurrent Neurological Events and Therapy
The risk of stroke recurrence after CS justifies a search for
effective preventive therapy. If PFO is felt to be a significant
factor, then either the pathway for possible paradoxical
embolization (the PFO) could be closed, or the formation of
embolic material could be reduced (anticoagulate, stop
scuba diving with techniques that allow nitrogen bubble
formation, remove central lines, etc). There are multiple
options for either approach. In most series, the risk of
recurrent CS with no form of treatment is approximately 6%
to 8% annually (with or without PFO). With either medical
treatment or PFO closure, the annual risk decreases to
approximately 2% to 4%. That recurrences are not com-
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surprising since CS undoubtedly has multiple, as yet un-
identified, potential etiologies. PFO may be 1 etiology, but
is seen in only about 50% of CS patients. About 20% of
patients who have CS from unrelated causes are expected to
have a PFO based on the incidence of PFO in the general
population. The real question at this time is whether
medical treatment, simple closure of the PFO or a combi-
nation of both approaches will be superior in terms of stroke
prevention, costs, and patient tolerance in different subsets
of patients.
Surgical therapy. The invasive nature of surgical interven-
tion for prevention of CS in patients with PFO renders it
generally less appealing than medical or transcatheter ther-
apy. Risks of perioperative complications, including ar-
rhythmias and bleeding, are significant technical hurdles.
Minimal data regarding this approach has been collected.
An annual combined stroke or TIA recurrence of 7.9% has
been reported after surgical PFO closure (24). Though
surgical closure of PFO is reportedly associated with a
reduced risk of recurrent stroke, there are no large experi-
ences. In addition, medical therapy is sometimes continued
after surgery, which may affect stroke recurrence risk.
Medical therapy. The optimal medical therapy for preven-
tion of recurrent CS is unknown. Numerous uncontrolled
studies have shown an apparent benefit of medical therapy
after a CS. However, the best medical treatment, antiplate-
let versus anticoagulant, remains controversial. WARSS
(Warfarin-Aspirin Recurrent Stroke Study) was the first
randomized controlled study to compare the effect of
warfarin and aspirin after prior noncardioembolic ischemic
stroke. WARSS showed aspirin was as good as warfarin in
prevention of stroke recurrence, but presence of PFO was
not specifically systematically evaluated (25). The majority
of subgroup analyses in the WARSS showed no benefit of
warfarin over aspirin. The PFO in Cryptogenic Stroke
Study found no difference in time to recurrent ischemic
stroke or death between patients randomized to aspirin or
warfarin (13). Warfarin anticoagulation carries greater hem-
orrhagic risk and more complex monitoring and therapeutic
adjustments, which can be a significant concern in many
patients. Importantly, both medical treatments are reported
to be associated with recurrent events after a CS. Annual
stroke/TIA recurrence rates of 3.8% to 12% with medical
treatment (oral anticoagulants or antiplatelet medication)
have been reported in various studies (14,25–27).
Transcatheter Therapy
The possibility of avoiding or improving the outcomes of
long-term anticoagulation is a potential benefit of PFO
device closure. Since the first report in 1992 (15), several
groups have described the safety and efficacy of PFO closure
using various transcatheter devices. Defining PFO anatomy
and careful evaluation of adjacent structures is important
during transcatheter closure. Therefore, echocardiographicimaging (TEE or intracardiac echocardiography) plays a
significant role for guidance during closure and is man-
datory for achieving optimal results. Intracardiac echo-
cardiography has the advantage of avoiding the need for
general anesthesia.
Reported complications of PFO device closure include
vascular injury, cardiac perforation or air embolization
during implantation, device embolization, early and late
thrombosis, and atrial arrhythmia. A large-sized device
should not be used for closure as it may not conform well to
the atrial anatomy, and may cause late complications by
impinging on surrounding structures (28). With the use of
contemporary devices, the incidences of complications are
low, but not negligible (29). Most of these complications are
preventable or transient and potentially can be avoided by
continued improvements in technique and device design. At
the present time, none of the available PFO closure devices
have been approved by the U.S. Food and Drug Adminis-
tration, and closures are performed off-label using devices
approved for other indications.
An annual recurrence rate of 0% to 5% for stroke or TIA
has been reported following PFO device closure (28,30,31).
An organized literature review of nonrandomized studies
found that the annual recurrence rate of stroke/TIA with
PFO device closure was 0% to 4.9% versus 3.8% to 12.0%
with medical therapy (27). Kutty et al. (28) analyzed the
results of investigations performed for neurological events
after PFO device closure and reported a combined recur-
rence rate of 3.4% for stroke/TIA and an event rate of 0.9%
per year for recurrent strokes. These studies suggest that the
recurrent stroke/TIA rates after PFO device closure are
comparable to rates from studies of recurrent events in
patients with PFO and CS treated with various regimens of
medical treatment (8); however, PFO closure has not yet
been proved superior to medical treatments. Despite enthu-
siasm for eliminating a theoretical cause of CS by PFO
closure, patients deserve a clear presentation of the uncertain
benefits of closing the PFO before proceeding. In discus-
sions with patients, it has to be emphasized that the
procedure would eliminate only 1 potential possible cause
for stroke.
As of now, there is no clear evidence on the utility of
transcatheter PFO closure devices in the treatment of
patients with CS or TIA and PFO. Further studies are
necessary to determine the potential efficacy of PFO closure
devices in this setting and to identify the patients who are
most likely to benefit from PFO closure.
Randomized Trials
Though the utility of transcatheter PFO devices for treat-
ment of patients with CS and PFO is unknown, there are a
wealth of uncontrolled data that show some improvement in
recurrent stroke rates with PFO closure as compared with
expected recurrence rates with no treatment. The magni-
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suffered a first CS. This similarity in effect with suboptimal
data is the ethical basis for currently ongoing randomized
trials of PFO closure compared to medical management.
CLOSURE I (Evaluation of the STARFlex Septal Clo-
sure System in Patients With a Stroke or TIA Due to the
Possible Passage of a Clot of Unknown Origin Through a
Patent Foramen Ovale), the first prospective, randomized,
independently adjudicated PFO device closure trial, has just
been completed (32). The trial was designed to test whether
PFO closure using STARFlex device (NMT Medical,
Boston, Massachusetts) plus medical therapy is superior to
medical therapy alone for preventing recurrent stroke or
TIA in patients with CS or TIA and a PFO. The trial
consisted of 909 patients60 years of age with a CS or TIA
nd a TEE-documented PFO, with or without ASA,
andomized at 87 sites across the United States and Canada.
ll patients did not have MRI, and presence of stroke versus
IA was mostly made on clinical grounds. The primary
ndpoints were 2-year incidence of stroke or TIA, all-cause
ortality for the first 30 days, and neurological mortality 31
ays to 2 years.
CLOSURE I failed to demonstrate superiority of PFO
evice closure plus medical therapy (6 months of aspirin and
lopidogrel followed by 18 months aspirin) over best med-
cal therapy (24 months warfarin or aspirin or combination).
he 2-year stroke rate was essentially identical in both study
rms (3%), with no significant benefit shown in the device
rm related to the degree of initial shunt or ASA. ASA was
ot shown to be a risk factor in this trial. Among patients in
he device arm, there were major procedure-related vascular
omplications (3%), but it should be noted that many of
he centers had little prior experience with transcatheter
FO closure techniques. There was a concerning rate of
eriprocedural atrial fibrillation (5.7%) with this particular
evice, which was not seen in other series from experienced
enters using this and other devices. The trial concluded
hat an alternative explanation unrelated to paradoxical
mbolism is present in 80% of patients with recurrent stroke
r TIA. This highlights the need for better standardized
valuations to detect alternative causes of CS and the need
or further studies to examine the potential efficacy of PFO
evice closure in better-defined patient populations.
Three other trials, PC-Trial (Patent Foramen Ovale and
ryptogenic Embolism), RESPECT (Randomized Evalu-
tion of Recurrent Stroke Comparing PFO Closure to
stablished Current Standard of Care Treatment), and
EDUCE (GORE HELEX Septal Occluder for Patent
oramen Ovale Closure in Stroke Patients), are ongoing.
he PC-Trial (NCT00166257) compares percutaneous
losure of PFO using the Amplatzer PFO Occluder (AGA
edical Corp., Plymouth, Minnesota) versus antithrom-
otic treatment (warfarin for 6 months followed by anti-
latelet agents). Randomization for the PC-Trial was strat-
fied by patient age, presence of atrial septal aneurysm, and
umber of prior embolic events; the chosen primary end-points being death, nonfatal stroke, and peripheral em-
bolism. Patient enrollment for this trial was completed in
2009, and an interim analysis is expected in 2012.
Endpoints of the RESPECT PFO trial (NCT00465270)
are cerebrovascular accident or death. The REDUCE trial
(NCT00738894) is designed to specifically compare anti-
platelet therapy alone versus antiplatelet with PFO closure
using the GORE HELEX septal occluder (W.L. Gore &
Associates, Flagstaff, Arizona) and uses hard endpoints of
brain MRI–confirmed recurrent stroke or TIA.
Enrollment in the aforementioned randomized trials has
been slow, possibly due to patient or physician preference
for a variety of reasons. Off-label device closure of PFO
outside of the trials is very common, particularly in subjects
deemed to be high risk due to various reasons, including age
or recurrence of neurological events. Even randomized trial
results are only generalizable if the trial population is
reasonably representative, so these practice patterns could
spuriously influence future trial outcomes. There is clearly a
need for more data to elucidate the best approach to the
treatment of patients with CS and PFO.
Relationship of PFO to Other Diseases
PFO has been associated with the pathophysiology of
several other disease states, including migraine headaches,
decompression sickness, peripheral embolism including
myocardial and renal infarction, and Alzheimer’s dementia.
Right-to-left shunting through a PFO can also greatly
worsen symptoms in patients with chronic lung diseases
associated with hypoxemia, or obstructive sleep apnea/sleep-
disordered breathing. In order of magnitude, the amount of
right-to-left shunting to cause systemic desaturation is
larger than the amount of shunting seen in the general
population with a PFO.
Migraines. Del Sette et al. (33) first reported an association
between migraine with aura and the presence of right-to-
left shunts detected with transcranial Doppler. The pre-
sumed association of PFO with migraines relates to paradox-
ical embolism or humoral factors that escape degradation in
bypassing the pulmonary circulation. Using transthoracic
echocardiography, it was shown that among divers with
decompression illness, those with large right-to-left shunts
had a higher prevalence of migraine with aura in everyday
life and after dives than those with no shunt or a smaller
shunt (34). A retrospective evaluation of the effect of
transcatheter closure of atrial shunts on migraine symptoms
suggested a causal association between right-to-left shunts
and migraine with aura, indicating that there may be a
subgroup of patients who have severe migraine associated
with a large right-to-left shunt in whom closure of the atrial
defect may reduce or abolish symptoms (35). Others have
reported complete resolution of migraines in 60% of pa-
tients and improvement in symptoms in 40% of patients
after transcatheter closure of atrial shunts (36). Wahl et al.
(37) evaluated migraine symptoms at a mean follow-up of 5
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catheter PFO closure for secondary prevention of paradox-
ical embolism. The prevalence of migraine with aura and the
number of patients on migraine medication decreased sig-
nificantly, suggesting beneficial reduction of symptoms,
especially in migraine with aura (37).
No association was found between migraines and the
presence of PFO in a recent, large case-control study (38).
Moreover, a real benefit of PFO closure for reducing the
frequency of migraines has not been shown in a randomized
trial. The MIST (Migraine Intervention With STARFlex
Technology) trial was a prospective, double-blind (control
patients had a sham procedure and evaluating physicians
were not supposed to be aware of whether a patient had a
device) trial that evaluated the effectiveness of PFO closure
in the treatment of migraine with aura (39). In MIST, 147
patients with a history of severe migraines and without any
other indication for PFO device closure were randomized to
undergo either device closure or a sham procedure. The
patients were treated with aspirin and clopidogrel. No
significant difference in the primary outcome of headache
cessation was detected between the 2 groups 3 to 6 months
after the procedure. On exploratory analysis, excluding 2
outliers, the closure group showed a greater reduction in
migraine headache days compared with the sham group.
These results could have been affected by several method-
ology and design reasons, including the selected primary
efficacy endpoint, the duration of follow-up, and the med-
ications used in both groups (39).
Two other trials, PRIMA (PFO Repair in Migraine
With Aura) and PREMIUM (Prospective Randomized
Investigation to Evaluate Incidence of Headache Reduction
in Subjects With Migraine and PFO Using the Amplatzer
PFO Occluder Compared to Medical Management), are
currently under way. Further investigations are necessary to
evaluate the causal relationship between migraines and
PFO, and until definitive results are available the role of
PFO device closure in the treatment of migraines is highly
debatable.
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